[ad_1]
 |
| © AFP = News1 |
The British Medical Journal called for an amendment to the New York Times report that the United States plans to inoculate different types of vaccines against infection with the new coronavirus (Corona 19) in combination.
The New York Times recently quoted several UK health officials as saying that it will allow the vaccine to receive a different type of vaccine if the Corona 19 vaccine that was given in the first vaccination was not available in the second. For example, it is reported that a person who received the AstraZeneca vaccine in the first dose may receive other vaccines such as the Pfizer vaccine in the second.
On the 3rd (local time), the BBC reported that Fiona Goodley, editor-in-chief of the British Medical Journal (BMJ), commented on the New York Times report as “serious misinformation” and “urgently in need of correction.”
Editor-in-chief Goodley explained that on December 31, the vaccination guidelines recommended by the Joint Committee on Vaccination and Immunization (JCVI) in the UK did not recommend the use of the COVID-19 vaccine.
British health authorities and the BMJ contested the New York Times report.
Mary Ramsey, head of vaccination at the British Department of Health (PHE), said on a PHE Twitter account on the 3rd (local time): “We do not recommend a combination of the COVID-19 vaccine.” You should not get vaccinated, and vice versa”.
However, if the same vaccine cannot be obtained, or if there is an “ extremely rare ” case of not knowing which vaccine was given at the time of the first vaccination, it is better to inject another vaccine than not to receive the second.
The Centers for Disease Control and Prevention (CDC) also recommended using a product that can be given if it is impossible to use the same manufacturer’s vaccine for the first and second doses.
In this regard, the national quarantine authorities stated that in principle both the first and second doses should be vaccinated with the same vaccine.
Jung Eun-kyung, head of the Central Defense Countermeasures Headquarters, said in a regular briefing on the 4th: “It is difficult to confirm what scientific foundations were made in the UK,” he said. “I think this is probably considering the introduction or delivery of vaccines.”
◇ AZD1222 vaccination starts from day 4 … Peak protein gene delivery using viral vectors
Meanwhile, according to the BBC, some 950,000 people have completed the first dose of the corona vaccine 19’BNT162b2 ‘from Pfizer, a multinational pharmaceutical company that started vaccination in the UK since last month, and Bioentech in Germany. The first vaccination of the AstraZeneca ‘AZD1222’ vaccine, which was approved on the 30th of last month, will begin on the 4th (local time).
AZD1222 uses an adenovirus vector that only infects chimpanzees as a carrier to transport the spike protein gene on the surface of Corona 19 virus into the cell. When the gene delivered in this way is expressed as a spike protein, it recognizes it as an antigen, and the generated antibody has a neutralizing effect even when the actual Corona 19 virus invades the body, protecting our body from the virus.
The UK Medicines and Healthcare Products Regulatory Authority (MHRA) recommended that a second vaccine be given 4 to 12 weeks after the first dose, and said safety and efficacy for children and adolescents under the age of 12 have not yet been established. 18 years.
The effectiveness of the AstraZeneca vaccine is on average 70.42%, which is slightly lower than the 95% of Pfizer and 94.5% of Modena who have started vaccination. However, unlike BNT162b2, which should be stored at -70 ° C (-70 ° C), it has the advantage of being able to be transported and stored at 2-8 ° C.
[ad_2]
